Murine Anti-mCTLA4 mAbAnti-mCTLA4-mIgG2a InvivoFit™Unit sizeCat. codeDocsPrice9D9-derived mouse monoclonal antibody against murine CTLA-49D9-derived mouse monoclonal antibody against murine CTLA-41 mg 10 mg mctla4-mab10-1mctla4-mab10-10TDSMSDSDATATDSMSDSDATA ¥4,586.00Please contact our distributorAdd to favorite ¥29,655.00Please contact our distributorAdd to favoriteAboutSpecificationsContentsDetailsRelated productsRecombinant mouse mAb against murine CTLA-4 for in vivo useEffect of Anti-CTLA4 on T cell activationAnti-mCTLA4-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCTLA-4 9D9 mAb [1] and a murine IgG2a constant region. The 9D9 mAb has a sequence that is 100% murine (constant and variable regions), ensuring minimal immunogenicity upon repeated injections into mice. This mAb targets murine cytotoxic T-lymphocyte-associated protein 4 (mCTLA-4) and blocks CTLA4-mediated negative signals downregulating T cell activation. Thus, anti-mCTLA-4 mAb unleashes T cell activity [1, 2].Notably, the 9D9 mAb, along with most commercially available anti-mCTLA4 mAbs feature the IgG2b isotype which displays low antitumor activity in vivo [2]. To overcome this issue, Anti-mCTLA4-mIgG2a InvivoFit™ was generated by recombinant technology and features the murine IgG2a isotype, which mediates potent cytotoxic functions. Anti-mCTLA4-mIgG2a is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies. Key features of Anti-mCTLA4-mIgG2a InvivoFit™:Sequence is 100% murineFeatures the IgG2a isotype (associated with high antitumor activity)Guaranteed sterile, endotoxin level < 1 EU/mgSpecifically designed for in vivo studies in miceLow aggregation < 5%Produced in both animal-free facilities and defined mediaAnti-mCTLA4-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells, purified by affinity chromatography with protein A, and it"s binding to mCTLA-4 is validated using ELISA. References:1. Selby MJ. et al., 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 1(1):32-42.2. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.Figures ELISA binding of Anti-mCTLA4-mIgG2a InvivoFit™ to recombinant murine CTLA-4. A dilution series of Anti-mCTLA4-mIgG2a InvivoFit™ and anti-mCTLA4 (9D9 clone) was used for the detection of coated mCTLA-4 antigen at 5 µg/ml. Detection of bound antibody was performed using an HRP‑conjugated anti‑murine κ-light chain secondary antibody. HRP activity was assessed by a colorimetric assay using Tetramethylbenzidine (TMB) substrate. Optical density was measured at 490 nm. Data are shown as percentage absorbance. Back to the topSpecificationsSpecificity: Targets cells expressing murine CTLA-4Formulation: Lyophilized from 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharoseClonality: Monoclonal antibodyIsotype: Murine IgG2a, kappaSource: CHO cellsPurity: Purified by affinity chromatography with protein ATested application: ELISAQuality control:Binding confirmed using ELISAThe complete sequence of this antibody has been verified< 5% aggregates (confirmed by size exclusion chromatography)Guaranteed sterile and <1 EU/mg (determined by the LAL assay)Back to the topContentsAnti-mCTLA4-mIgG2a InvivoFit™ is provided sterile, endotoxin-free, azide-free and lyophilized. This product is available in two pack sizes:mctla4-mab10-1: 1 mgmctla4-mab10-10: 10 mg Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for at least 1 year Avoid repeated freeze-thaw cycles.Back to the topDetailsThe cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) is an inhibitory receptor expressed on activated T lymphocytes. T-cell activation requires two signals. Signal 1 is delivered upon interaction of the T cell receptor (TCR) with antigenic peptides bound to major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). Signal 2 is delivered upon interaction of the co-stimulatory receptor CD28 with the B7 family ligands, B7-1 (CD80) and B7-2 (CD86), on APCs.CTLA-4 is an immune checkpoint molecule upregulated upon T cell activation. It exerts competitive binding to CD28 ligands, thereby preventing T-cell overstimulation. CTLA-4 blockade with monoclonal antibodies (mAbs) has been used to treat patients with metastatic melanoma.Back to the topYou may also needRaji-hCTLA4 CellsHuman lymphoblast cells - ADCC CTLA-4 Target CellsAnti-hCTLA4 isotype familyFamily of antibodies against human CTLA-4Mouse IgG2a Controlβ-galactosidase antibody (isotype control) - Mouse IgG2a
Invivogen公司的Plasmocin™属于新一代杀菌抗生素,能强烈的作用于感染支原体的细胞,杀灭支原体。同时,Plasmocin™能以一种较低的作用浓度发挥广谱的抗革兰氏阳性和革兰氏阴性的细菌作用,比如能作用于耐青霉素与链霉素的细菌,已经证实Plasmocin™对真核细胞没有毒性。
Plasmocin™包括两种新的杀菌成份,一种能作用于原核细胞的蛋白系统,另一种能干扰DNA的复制,因为Plasmocin™能以两种独立的特殊的方式作用靶原核细胞,可完全的去除支原体感染。和其他的抗支原体抗生素比较,Plasmocin™能同时作用于细胞内与细胞外的,因为Plasmocin™能有效地杀灭哺乳动物细胞感染的支原体,并不影响细胞本身的代谢,用Plasmocin™处理过的培养细胞,不会重新感染(从其他感染支原体细胞释放的)支原体。
支原体污染去除试剂:货号为ant-mpt:Plasmocin™ treatment,50 mg (2 x 1 ml),作用浓度为25μg/ml(1000x稀释)。
支原体预防试剂:货号为ant-mpp:Plasmocin™ prophylactic,25 mg (10 x 1 ml),作用浓度为5μg/ml(500x稀释)。
产品信息如下:
品牌 | 货号 | 产品名称 | 规格 | 价格 |
InvivoGen | ant-mpt | Plasmocin™ treatment | 50 mg (2 x 1 ml) | 询价/现货 |
InvivoGen | ant-mpp | Plasmocin™ prophylactic | 25 mg (10 x 1 ml) | 询价/现货 |
其他相关产品还有:
1.Normocin™ 能预防支原体,细菌和真菌。
2.Fungin™ 预防和清除真菌。
3.Primocin™ 预防支原体,细菌和真菌:专为原代培养的细胞而设计。
4.Plasmocure™ 是Plasmocin的新一代产品,能在极少数支原体对Plasmocin耐受的情况下发挥作用。
产品信息如下:
品牌 | 货号 | 产品名称 | 规格 | 价格 |
InvivoGen | ant-nr-1 | Normocin™ | 500 mg (50 mg/ml) | 询价 |
InvivoGen | ant-fn-1 | Fungin™ | 75 mg (5 x 1.5 ml) | 询价 |
InvivoGen | ant-pm-1 | Primocin™ | 500 mg (10 x 1 ml) | 询价 |
InvivoGen | ant-pc | Plasmocure™ | 100 mg | 询价
|